On a consolidated basis, revenue climbed 23% year-on-year to ₹425 crore, up from ₹345 crore. EBITDA surged 73.4% year-on-year, reaching ₹108 crore compared to ₹62.3 crore, while margins improved to 25.4% from 18% in the previous year’s quarter.
The company noted an 11% year-on-year increase in patient volumes, with test volumes rising by 14% year-on-year, driven by increased demand, enhanced market penetration, and improved clinician engagement.
ALSO READ | Metropolis Health shares see nearly 5% increase following positive Q3 business update
B2C revenues grew 20% year-on-year, fueled by a greater adoption of preventive and specialized testing, enhanced digital engagement, and targeted marketing initiatives. B2B revenues rose 28% year-on-year, bolstered by client retention, hospital outsourcing opportunities, robust partner relationships, and improved service consistency.
The TruHealth portfolio of the company expanded by 24% year-on-year, while the specialty portfolio experienced a 31% year-on-year growth, indicating a rising consumer preference for preventive healthcare and advanced diagnostics.
Revenue per patient (RPP) saw an 11% year-on-year improvement, while revenue per test (RPT) rose 8% year-on-year, benefiting from a favorable mix and increased contributions from specialized testing.
ALSO READ | Metropolis Healthcare Q2 net profit rises 13% on TruHealth and specialty portfolio growth
The company attributed its margin expansion and profitability enhancements to strong demand and operational efficiencies. It also surpassed the milestone of over 5,000 centers, enhancing accessibility and market presence across India.
A second interim dividend of ₹1 per equity share of face value ₹2 has been declared for the financial year 2025-26. The record date for determining shareholder eligibility for the interim dividend is set for Tuesday, May 19, 2026. Payment will be conducted within 30 days of the declaration.
Ameera Shah, Promoter and Executive Chairperson of Metropolis Healthcare Ltd, stated, “The diagnostics industry in India is transitioning towards more organized and science-driven platforms, spurred by a greater emphasis on trust, accuracy, and clinical excellence. At Metropolis, our commitment to scientific excellence, strong doctor partnerships, and advanced diagnostics positions us advantageously in this evolving healthcare landscape,” adding, “In Q4FY26, Metropolis achieved substantial growth, with revenue increasing by 23% YoY, while expanding our network to over 5,000 centers across India.”
ALSO READ | Metropolis Healthcare targets 13-15% revenue growth in FY26 driven by preventive and specialty initiatives
On May 13, shares of Metropolis Healthcare Ltd closed at ₹550, up by ₹2, or 0.36%, on the BSE.
